LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Buy” by Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $94.40.

A number of equities research analysts have recently issued reports on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective on the stock. JMP Securities boosted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $92.00 price objective on shares of LeMaitre Vascular in a research report on Friday, September 20th.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 12,976 shares of the business’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total transaction of $1,116,844.32. Following the completion of the sale, the chief executive officer now directly owns 1,985,358 shares of the company’s stock, valued at $170,879,763.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,251 shares of company stock valued at $3,714,994 over the last ninety days. Corporate insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

A number of institutional investors and hedge funds have recently modified their holdings of LMAT. YHB Investment Advisors Inc. acquired a new stake in shares of LeMaitre Vascular in the first quarter worth $36,000. GAMMA Investing LLC lifted its stake in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 199 shares during the last quarter. West Oak Capital LLC acquired a new stake in shares of LeMaitre Vascular in the second quarter worth $58,000. USA Financial Formulas acquired a new stake in shares of LeMaitre Vascular in the third quarter worth $60,000. Finally, nVerses Capital LLC lifted its stake in shares of LeMaitre Vascular by 33.3% in the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $90.39 on Wednesday. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $93.24. The company’s 50 day simple moving average is $87.70 and its 200 day simple moving average is $80.17. The company has a market capitalization of $2.03 billion, a P/E ratio of 59.86, a PEG ratio of 2.41 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same quarter in the previous year, the business earned $0.37 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. On average, analysts anticipate that LeMaitre Vascular will post 1.85 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were given a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.71%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is 42.38%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.